Chemical fingerprint analysis for quality control of Fructus Aurantii Immaturus based on HPLC-DAD combined with chemometric methods

Xiaona Xu ab, Junhui Jiang b, Yizeng Liang *a, Lunzhao Yi a and Jinle Cheng c
aCollege of Chemistry and Chemical Engineering, Research Center of Modernization of Chinese Medicines, Central South University, 410083, Changsha, Hunan, People's Republic of China. E-mail: yizeng_liang@263.net; Fax: +86-731-8825637
bCollege of Chemistry and Chemical Engineering, University of South China, 421001, Hengyang, Hunan, People's Republic of China
cZhongzhi pharmaceutical limited company, 528415, Zhongshan, Guangdong, People's Republic of China

Received 20th July 2010 , Accepted 23rd September 2010

First published on 15th October 2010


Abstract

High-performance liquid chromatographic (HPLC) fingerprints of 12 authentic samples and 26 commercial samples of Fructus Aurantii Immaturus (FAI) from different sources of China were measured. Firstly, the main bioactive compounds in citrus herb, namely naringin and hesperidin, were identified and quantitated. Then, principal components analysis (PCA) was performed to differentiate and classify the studied samples based on the principal peaks and entire chromatograms, respectively. Hierarchical clustering analysis (HCA) and similarity analysis (SA) were further conducted to validate the clustering results. The optimized HPLC-DAD method aided by forementioned chemometric methods shows that the chemical fingerprints of 38 samples from extensive sources could be reasonably identified and systematically analyzed, which offers a new clue for the study of traditional Chinese medicines (TCM). The results obtained will provide a useful foundation for quality control of herbal medicine.


1 Introduction

Fructus Aurantii Immaturus (FAI) is an effective traditional Chinese medicine (TCM) used for more than 2000 years in the treatment of dissipating stagnant qi, removing qi stagnation, eliminating sputum and dispersing painful abdominal mass. It is the dried, unripe fruit of Citrus aurantium L., cultivated variety or citrus sinensis Osbeck of Rutaceae, often called Zhishi in Chinese and officially listed in the Chinese Pharmacopoeia.1 Flavonoids, alkaloids and essential oil components are the major bioactive compositions in this herb. Hesperidin and naringin, the important representative flavonoids in citrus herb, possess antioxidant, anti-inflammatory and anti-ulcer properties as most flavonoids do.2–4

It is well known that traditional Chinese medicines (TCMs) contain multiple chemical components, each of which may be relevant to the medicine's putative activity. The various origins, different processing procedures, saving conditions and deposited year may lead to the difference in the contents of chemical constituents and compound denominations of herbal medicine, which may directly influence therapeutic effects. Therefore, discrimination of an herbal material's origin as well as determination of its bioactive ingredients is crucial in order to ensure its authenticity, quality, safety and efficacy. Until now, besides macroscopic and microscopic authentication, chemical identification of herbal materials with various pattern recognition methods, such as similarity analysis (SA), hierarchical clustering analysis (HCA) and principal component analysis (PCA), is increasingly employed to discriminate the habitats of raw herbal materials.5–12

Publications about FAI are mostly about one or several compounds' qualitation and quantification in HPLC-UV, HPLC-UV-MS and HPLC-MS-MS, mainly hesperidin, naringin and synephrine.13–18 Although there are some publications associated with the fingerprints of FAI, none of them involved systemic comparison among different herbal origins, identification using characteristic chemical compounds or a discrimination model. In the present study, a HPLC fingerprint method in combination with chemometric methods to analyze FAI from various origins was described. To begin with, the main bioactive compounds in citrus herb, namely naringin and hesperidin, were identified and quantitated. Then, principal components analysis (PCA) was performed to differentiate and classify the studied samples based on the principal peaks and entire chromatograms, respectively. Then, hierarchical clustering analysis (HCA) and similarity analysis (SA) were further conducted to validate the clustering results adjunctively. Finally, the HPLC fingerprints of 38 samples from extensive sources were roundly analyzed and identified. This investigation shows that the developed methodology can be generalized in the research of quality control of herb medicines. The results obtained may also provide a useful chemical basis for future research of this herb.

2 Experimental

2.1 Chemicals and reagents

The standards of hesperidin (batch number 0721-9909) and naringin (batch number 0722-9805) were purchased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Their chemical structures are shown in Fig. 1. HPLC grade methanol, acetonitrile and polyphosphoric acid were purchased from Jiangsu Hanbon Science and Technology Co., Ltd (Huaian, Jiangsu Province, China). Other reagents were of analytical grade. Water was deionized in a Milli-Q water purification system (Millipore Bedford, MA, USA).
Chemical structures of naringin and hesperidin.
Fig. 1 Chemical structures of naringin and hesperidin.

2.2 Plant materials

Thirty-eight batches of samples from eighteen provinces and one municipality of China including 12 authentic samples and 26 commercial samples were authenticated morphologically and microscopically as Fructus Aurantii Immaturus by Mr. Xiangqian Liu, working at Central South University, Changsha, Hunan, P. R. China (see Table 1). Voucher specimens were preserved at our lab.
Table 1 Collection information of the studied samples
Sample no. Sources Habitat Production time
01 Purchased from Xian, Shanxi Jiangxi 2008
02 Purchased from Jinxiang Drug Store, Beijing unknown 2008
03 Purchased from Zhonglian Drug Store, Wuhan, Hubei Jiangxi 2009
04 Purchased from Hefei, Anhui unknown 2009
05 Purchased from Shengyuan Drug Store, Nanning, Guangxi Hunan 2008
06 Purchased from Changchun, Jilin Hunan 2009
07 Purchased from Hengkang pharmaceutical company, Yiyang, Hunan unknown unknown
08 Hunan (authentic sample) Hunan 2009
09 Hunan (authentic sample) Hunan 2009
10 Purchased from, Yunnan Yunnan 2009
11 Purchased from Dongbei Drug Store, Shenyang, Liaoning Hunan 2009
12 Purchased from Taiyuan, Shanxi Unknown 2008
13 Xinyu, Jiangxi (authentic sample) Jiangxi 2009
14 Xinyu, Jiangxi (authentic sample) Jiangxi 2009
15 Purchased from Guilin, Guangxi Hunan 2008
16 Purchased from Haikou, Hainan Unknown 2008
17 Purchased from Harbin, Heilongjiang Unknown 2008
18 Purchased from Kangtai Drug Store, Hengyang, Hunan Unknown 2009
19 Qingjiang, Jiangxi (authentic sample) Jiangxi 2009
20 Qingjiang, Jiangxi (authentic sample) Jiangxi 2009
21 Purchased from Huaihua, Hunan Hunan 2008
22 Purchased from Zhuji, Zhejiang Unknown 2008
23 Purchased from Xining, Qinghai Unknown 2009
24 Purchased from Xinjiang unknown 2008
25 Deyang, Sichuan (authentic sample) Sichuan 2009
26 Deyang, Sichuan (authentic sample) Sichuan 2009
27 Purchased from Xian, Shanxi Jiangxi 2008
28 Purchased from Linxin, Shandong Jiangxi 2009
29 Purchased from Chenzhou, Hunan unknown 2009
30 Purchased from Chenzhou, Hunan unknown 2008
31 Purchased from Dongguan, Guangdong Hunan 2008
32 Purchased from Kunming City zhongyiyuan, Yunnan Unknown Unknown
33 Purchased from Yiyang, Hunan Hunan 2008
34 Panxi, Yunnan (authentic sample) Yunnan 2009
35 Panxi, Yunnan (authentic sample) Yunnan 2009
36 Purchased from Lanzhou, Gansu Unknown 2009
37 Yiyang, Hunan (authentic sample) Hunan 2008
38 Yiyang, Hunan (authentic sample) Hunan 2008


2.3 Preparation of standard and sample solutions

The reference compounds were weighed accurately and dissolved in methanol in a 10 mL volumetric flask to make stock solutions. Working standard solutions were prepared from those stock solutions by further dilution with the appropriate volume of methanol. These solutions were stored away from light at 4 °C in a refrigerator.

Pulverized sample (60 mesh, 0.5 g) was weighed accurately into a 150-mL round bottom flask, then extracted for 10 min at room temperature under ultrasound with 25 mL methanol and finally filtered. The extraction was repeated two additional times. The extracts were combined and preserved in refrigerator.

All standard solutions, samples and solvents used for HPLC measurements were filtered through a 0.22 μm nylon filter membrane before HPLC analysis.

2.4 Instrumentation and chromatographic conditions

An ultrasonic cleaner made in Kunshan ultrasonic Instrumentation Factory (Kunshan, Jiangsu, PR China) was used for extraction. All HPLC analyses were performed using Agilent/HP 1100 Series HPLC-DAD system consisting of a vacuum degasser, quaternary pump, manual-sampler, thermostated column compartment and DAD (Agilent, Palo Alto, CA, USA). A Sepax C18 (5 μm, 250 mm × 4.6 mm) column protected by a suitable guard column (C18, 5 μm, 7.5 mm × 4.6 mm) were used for all chromatographic separations. The mobile phase consisted of acetonitrile, methanol and 0.05% polyphosphoric acid water using a gradient program (see Table 2). The flow rate was 0.8 mL min−1, column temperature was maintained at 30 °C and the injection volume was 20 μL. The DAD detector was set at 284 nm for acquiring chromatograms. UV spectra were acquired from 200 to 400 nm.
Table 2 The gradient elution program
Gradient/min A (CH3CN)% B (CH3OH)% C (0.05% H3PO4–H2O)%
0 6.0 3.0 91.0
10 16.0 13.0 71.0
30 16.0 13.0 71.0
35 18.0 18.0 64.0
45 25.0 35.0 40.0
70 25.0 70.0 5.0
80 25.0 70.0 5.0


2.5 Data analysis

2.5.1 Similarity analysis (SA) and hierarchical clustering analysis (HCA). Chromatographic fingerprints have been used to check for authenticity or provide quality control of herbal medicine and utilizes the advantage of chromatography to separate a complicated system into relatively simple sub-systems and then presents the chemical patterns of the herbal medicine in the form of a chromatogram.19–21 Methods, proposed to evaluate the similarity or difference of herbal medicines, can be viewed as forms of similarity analysis of the fingerprints.22–30 It is widely accepted as a key technique in quality control of traditional Chinese medicine. In this paper, the conventional correlation coefficient is used for this purpose.

HCA is an unsupervised statistical method, which provides a way to classify target objects into several groups based on measured characteristics. It starts with each sample in a separate cluster and then combines the clusters sequentially, reducing the number of clusters at each step until only one cluster left. When there are N samples, there involves N − 1 clustering steps or fusions. This hierarchical clustering process can be delineated as a tree or dendrogram, where each step in the clustering process is illustrated by a joint of the tree.31–33 In this study, the similarity measure is usually represented by the distance between two samples. The shorter distance between two samples represents their higher similarity.

2.5.2 Principal component analysis (PCA). PCA, another unsupervised statistical method, is widely used for reorganizing information as well as explaining causes of variance in a set of data.34,35 It aims to find linear transformations of original variables describing a set of samples, into new uncorrelated variables able to separate them in distinct groups according to specific similarities. These new variables are called principal components (PC). The first PC is the direction through the data which explains the most variation in the data, while the second PC is orthogonal to the first and describes the maximum amount of variability that is remaining. The following PCs are constructed as orthogonal to the anterior (uncorrelated) and with the maximum possibility of the remaining variance of the data set. When N is the number of initial variables, N PCs is obtained in all. The choice to number of PCs which adequately summarizes the data set is usually just enough to explain some large percentages of the total variation of the variables. Thus the goals of PCA are to simplify and enable data reduction, classify, determine similarities or relationships among the variables, as well as detect outliers.

All the data were pretreated including background deduction, smoothing and the chromatograms' alignment before SA, HCA and PCA.

3 Results and discussion

3.1 Optimization of extraction and chromatographic conditions

The efficiency of the extraction procedure was evaluated by using various extraction solvents and different extraction methods. Ethanol, methanol, and their respective different ratio aqueous solutions were used to extract the herb material respectively, and three extraction techniques, say maceration, reflux and ultrasound, were carried out. The results demonstrated that the optimum solvent was found to be anhydrous methanol, and ultrasound was validated as the optimal extraction method, both of which enabled less interfering peaks, and provided the biggest peak area of the principal peaks and peak number.

A method involving three-factor-three-level orthogonal array design (OAD) including the components of volume of methanol (5, 15, and 25 mL), times of ultrasound (one, two and three times) and duration of extraction (10, 30, and 60 min) was developed for the optimization of the extraction. The results demonstrated that the established extraction method was adequate and appropriate for the analysis (see Table 3).

Table 3 Result of orthogonal array design assay (OA9(33)) for extractsa
No. Factors Total extraction rate (%)
A B C
a A: Extraction number; B: Extraction time (min); C: Ratio of liquid to solid. b K i = ∑total extraction rate at Ai; the sum of the total extraction rates for a certain factor at each level. c R is the extreme difference of Ki (i = 1, 2, 3) for a certain factor.
1 1 (1) 1 (10) 1 (10) 13.63
2 1 2 (30) 2 (30) 16.52
3 1 3 (60) 3 (50) 17.11
4 2 (2) 1 2 17.88
5 2 2 3 17.58
6 2 3 1 17.15
7 3 (3) 1 3 19.87
8 3 2 1 17.04
9 3 3 2 17.01
K 1 47.26 51.10 47.82
K 2 48.61 51.14 51.41
K 3 53.92 51.27 54.56
R 7.16 0.17 6.74


The optimization of the chromatographic conditions was performed by using the sample solution. The investigated compounds were tested and compared by using different analytical columns (Phenomenex LUNA C18, Agilent XDB-C8 or Sepax C18) with different mobile phases (acetonitrile–water, methanol–water, and acetonitrile–method–water) and different gradient elution programs. The results showed that Sepax C18 column with gradient elution of acetonitrile–method–water could efficiently separate the investigated markers. Considering the presence of flavonoids in the herbal extraction, 0.05% phosphoric acid was added to the mobile phase to reduce the ionization and lower the polarity of these compounds. According to the UV spectra recorded by DAD from 200 to 400 nm, 284 nm was finally chosen to achieve chromatographic fingerprint profiles and detection wavelength based on the peak area of principal peaks and peak number. The representative HPLC-DAD chromatograms of mixed standards and the extract of FAI are shown in Fig. 2.


Representative HPLC-DAD chromatograms of mixed standards and the extract of Fructus Aurantii Immaturus (sample no. 32 in Table 1). Peak 2 and 3 are naringin and hesperidin, respectively. Peaks 1, 4 and 5 are also flavonoids compounds according to the similarities of their UV spectra with the standards naringin and hesperidin, they displaying the characteristic UV maximum absorbance of flavonoids. For terseness, the identification courses of the three peaks forementioned are omitted in this paper.
Fig. 2 Representative HPLC-DAD chromatograms of mixed standards and the extract of Fructus Aurantii Immaturus (sample no. 32 in Table 1). Peak 2 and 3 are naringin and hesperidin, respectively. Peaks 1, 4 and 5 are also flavonoids compounds according to the similarities of their UV spectra with the standards naringin and hesperidin, they displaying the characteristic UV maximum absorbance of flavonoids. For terseness, the identification courses of the three peaks forementioned are omitted in this paper.

3.2 Validation of the HPLC method

Each calibration curve was performed with six different concentrations of chemical markers. The square of all the correlation coefficients (r2) of these calibration curves were higher than 0.999. The limits of detection (LOD) and quantification (LOQ) were determined at a signal-to-noise ratio (S/N) of 3 and 10, respectively. The data were summarized in Table 4. Precision (inter-day and intra-day), repeatability, stability and recovery were all carried out to validate the HPLC method, following some reports on determination analysis.36–38
Table 4 The regression equations and detection limits for hesperidin and naringin
Compound Regression equation Correlation coefficient Linear range/μg mL−1 LOD/μg mL−1 LOQ/μg mL−1
hesperidin Y = 5.048 × 104X − 175.3 0.9992 2–300 0.05 0.16
naringin Y = 5.207 × 104X − 128.1 0.9995 2–256 0.06 0.19


3.3 Sample analysis

The established analytical method was applied to determine the contents of naringin and hesperidin in the 38 samples, which are the main bioactive ingredients in citrus herb. Identification of the compounds forementioned of the tested samples was based on comparing their UV spectra and their retention time with those of the standards. The contents of naringin and hesperidin in the tested samples were listed in Table 5. The measurable concentration ranges of the two components were in 0.143–6.267 and 1.355–9.456 mg g−1, which demonstrated the striking concentration disparity of naringin and hesperidin in herbal materials. The highest contents of the two bioactive compounds are more than five times the lower ones, respectively. Even in some samples naringin had not been detected or existed with very small contents so that it could not be accurately quantitated. Such consequences were in line with the Ref. 39. Flavonoids are the major effective ingredients in citrus herb, of which naringin and hesperidin are of conclusive therapeutic effect.40–42 Therefore, the quantitation standards of the two compounds above-mentioned should be instituted by correlative institutions as soon as possible, which will be a great assistance to quality control of this herb. Further studies are required to find out the influence of the compounds' concentration diversity of TCM on the therapeutic effect.
Table 5 The contents of naringin and hesperidin in the studied samples (n = 3)a
Sample no. Contents/mg g−1 ± S.D.
Naringin Hesperidin
a Sample no. corresponds to Table 1.
01 3.335 ± 0.011 6.176 ± 0.022
02 2.920 ± 0.003 5.317 ± 0.015
03 4.828 ± 0.007 1.355 ± 0.001
04 2.836 ± 0.005 1.526 ± 0.002
05 0.160 ± 0.001 7.060 ± 0.002
06 trace 7.907 ± 0.028
07 2.781 ± 0.004 4.693 ± 0.009
08 0.210 ± 0.001 8.198 ± 0.017
09 0.299 ± 0.001 7.873 ± 0.024
10 trance 6.632 ± 0.015
11 0.271 ± 0.002 8.686 ± 0.051
12 3.667 ± 0.017 2.062 ± 0.002
13 5.851 ± 0.021 1.526 ± 0.002
14 4.718 ± 0.004 1.840 ± 0.003
15 trace 6.946 ± 0.007
16 0.143 ± 0.000 5.577 ± 0.006
17 trace 2.867 ± 0.005
18 0.340 ± 0.001 6.062 ± 0.006
19 5.935 ± 0.001 2.468 ± 0.002
20 6.267 ± 0.006 1.549 ± 0.007
21 0.165 ± 0.000 7.973 ± 0.006
22 2.693 ± 0.003 2.627 ± 0.002
23 0.149 ± 0.000 9.456 ± 0.010
24 trace 7.000 ± 0.006
25 0.160 ± 0.000 7.060 ± 0.004
26 0.487 ± 0.001 6.886 ± 0.010
27 4.717 ± 0.005 5.634 ± 0.009
28 3.075 ± 0.002 4.966 ± 0.005
29 3.324 ± 0.001 3.637 ± 0.003
30 3.704 ± 0.002 2.624 ± 0.001
31 trace 6.436 ± 0.003
32 0.951 ± 0.000 4.667 ± 0.002
33 0.277 ± 0.001 6.658 ± 0.013
34 trace 7.427 ± 0.008
35 trace 6.547 ± 0.007
36 0.697 ± 0.005 7.685 ± 0.009
37 0.264 ± 0.001 7.300 ± 0.007
38 0.215 ± 0.000 7.060 ± 0.06


3.4 Principal component analysis (PCA)

3.4.1 PCA of samples based on principal peaks. To survey the distribution of the 38 samples, PCA was utilized to analyze and classify those HPLC-DAD data. The scores plot of PC1 versus PC2 was examined. First, the 2D-projection plot of PCA based on the five principal peaks (marked in Fig. 2) is shown in Fig. 3. Except sample no. 30, all the rest ones apparently form into two groups. The authentic samples (No. 13, 14, 19 and 20) from Jiangxi are clustered into group I as well as the commercial ones (No. 01–04, 12, 22, 27–29), and authentic samples nos. 08, 09, 37, 38 from Hunan cluster into group II including the authentic ones No. 25 and 26 from Sichuan, 34 and 35 from Yunnan, and the residuary commercial ones. The samples studied visibly clustered into groups based on the centers of Jiangxi's and Hunan's ones respectively. Obviously, No. 30 is detected as an outlier, which is a questionable sample. Herbal medicine from different origins have different chemical properties, thus different clusters come into being. Using the main peaks of fingerprints to do PCA can basically discriminate the sources of herbal materials.
PCA projection plot for the 38 samples, using peak areas of 5 principally common components as input data (peaks 1–5 in Fig. 2).
Fig. 3 PCA projection plot for the 38 samples, using peak areas of 5 principally common components as input data (peaks 1–5 in Fig. 2).
3.4.2 PCA of samples based on entire chromatograms. In order to investigate the influence of other peaks on cluster and validate the grouping results forementioned, entire chromatograms of the 38 samples are further employed to do PCA (see Fig. 4). The results obtained demonstrate that most samples are kept in the similar clustering state comparison to the sorting results based on the five principal peaks above mentioned. However, sample no. 32 is shown to be an outlier together with No. 30. It appears that when employing PCA to cluster herbal materials, the input data with entire chromatograms are better than that of several principal peaks, which exhibits stronger ability to display the chemical characters of samples.
The scatter plot obtained by PCA of the tested samples based on entire chromatograms.
Fig. 4 The scatter plot obtained by PCA of the tested samples based on entire chromatograms.

All programs of PCA were coded in MATLAB 6.5 for windows.

3.5 Hierarchical clustering analysis (HCA)

In order to judge the reliability of the categorization results of PCA forementioned and compare them with those of other classification methods, HCA was utilized to classify those 38 fingerprints. Centroid Euclidean distance was selected as a measurement. The hierarchical clustering was done by Traditional Chinese medicine quality control system/extendable data base, which was developed by our laboratory. A dendrogram was generated (see Fig. 5), which revealed the relationships among the studied samples. Generally, the thirty-eight chromatograms were divided into two basal clusters. The authentic samples (No. 13, 14, 19 and 20) from Jiangxi together with sample nos. 1–4, 7, 12, 22 and 27–30 were in group I and the other samples including the authentic samples from Hunan were in group II, which was again divided into subgroups, respectively. Sample nos. 1–4, 7, 12–14, 19, 20, 22, and 27–29 were in subgroup A, 30 and 32 was in subgroup B and D respectively, and the rest ones centered by the authentic samples from Hunan, Sichuan and Yunnan, were in subgroup C. The results of HCA indicated that samples which had similar chemical profiles were divided into one group. Here, sample nos. 30 and 32 are again discriminated as singular points. The result of HCA is similar with that of PCA based on entire chromatograms, and further confirms the latter. Both of them were based on entire fingerprints when classification done. It is obvious that overall fingerprints have larger abilities to reveal the variability of the tested samples than partial principal peaks when conducting discrimination analysis.
The result of hierarchic clustering analysis.
Fig. 5 The result of hierarchic clustering analysis.

3.6 Similarity analysis of HPLC fingerprints

Based on the definition of the fingerprint of TCM, a chromatographic fingerprint is actually a chromatographic pattern of some common kinds of pharmacologically active and chemically characteristic components in the TCM. “Integrity” and “fuzziness” are two fundamental attributes of fingerprints of TCMs. With the help of chromatographic fingerprints, the authentication and identification of herbal medicines can be conducted, even if the quantity of the chemically characteristic constituents are not exactly the same among different samples. The chromatographic fingerprints reveal both the “sameness” and “differences” between various samples successfully. In this study, the 38 samples from different origins in China were analyzed under the optimum chromatographic conditions.

Similarity analysis is a conventional method describing the similarity and dissimilarity among the fingerprints quantitatively. Here, similarity analysis was carried out on the 38 fingerprints by a Traditional Chinese medicine quality control system/extendable database developed by our laboratory. The correlation coefficient of similarity between each chromatographic profile of FAI samples and the simulative median chromatogram was calculated and generated, respectively (see Table 6). According to the results of Table 6, taking 0.90 as an appropriate threshold, the samples with the correlation coefficients above it will be clustered to a group, and those below it will be sorted to another group, which has been properly proved by the previous cluster results from PCA and HCA.

Table 6 The similarities of the studied samples
Samplea Similaritiesb
a The sample number from 01 to 38 are corresponding to the serial numbers as listed in Table 1. b The correlation coefficient was calculated based on the information obtained from the median of all chromatograms.
01 0.522
02 0.707
03 0.182
04 0.223
05 0.979
06 0.984
07 0.505
08 0.996
09 0.998
10 0.993
11 0.995
12 0.274
13 0.199
14 0.264
15 0.992
16 0.994
17 0.964
18 0.998
19 0.180
20 0.181
21 0.994
22 0.384
23 0.989
24 0.990
25 0.997
26 0.998
27 0.483
28 0.539
29 0.420
30 0.537
31 0.994
32 0.954
33 0.994
34 0.990
35 0.992
36 0.993
37 0.997
38 0.995


In order to see the details in the fingerprints, the median chromatograms of the two groups of FAI together with the two outliers are shown in Fig. 6. Peaks that existed in all chromatograms are considered as “common peaks”, indicating the sameness among various samples. 18 peaks coexisting in the 38 samples are indicated for visual comparison of the tested samples. Among the common components, the contents of hesperidin and narirutin are relatively high and stable, which were in correspondence with the literatures reported.11–13 Peak M and N existing in Fig. 6 (1) are not found in Fig. 6 (2), while peak P emerging in Fig. 6 (2) does not exist in Fig. 6 (1). Furthermore, there are many tiny peaks in Samples no. 30 and 32 with the retention time range 40–70 min (see Fig. 6 (3) and Fig. 6 (4)). The non-common peaks in each chromatogram represent the fuzziness among the same kind of TCM along with the different contents of the same component existing in the samples examined. It is in accordance with the theory that the secondary metabolites of plant herbs would clearly vary in different locations. Chinese medicine theory emphasizes synergism of multiple components to enhance remedy, lower toxicity and prevent side effects. Different constituents synergistically interact together and generate different curative effects. Further work should be probed on the variance of pharmacodynamic action of FAI from different origins.


Mean chromatograms of (1) 4 authentic samples including four from Jiangxi (sample no. 12, 13, 19 and 20) and 10 commercial samples (sample no. 1–4, 7, 14, 22, 27–29); (2) 6 authentic samples including four from Hunan (sample no. 08, 09, 37 and 38) and 2 from Sichuan (sample no. 34 and 35), and 2 from Yunnan (sample no. 25 and 26), and 16 commercial samples. (3) and (4) are the chromatograms of sample no. 30 and 32 (commercial samples), respectively. The sample numbers were coincident in Table 1. The five peaks 6–9 and 11 are corresponding to peaks 1–5 in Fig. 2, respectively. The other compounds cannot be identified.
Fig. 6 Mean chromatograms of (1) 4 authentic samples including four from Jiangxi (sample no. 12, 13, 19 and 20) and 10 commercial samples (sample no. 1–4, 7, 14, 22, 27–29); (2) 6 authentic samples including four from Hunan (sample no. 08, 09, 37 and 38) and 2 from Sichuan (sample no. 34 and 35), and 2 from Yunnan (sample no. 25 and 26), and 16 commercial samples. (3) and (4) are the chromatograms of sample no. 30 and 32 (commercial samples), respectively. The sample numbers were coincident in Table 1. The five peaks 6–9 and 11 are corresponding to peaks 1–5 in Fig. 2, respectively. The other compounds cannot be identified.

4 Conclusions

The developed chromatographic method had been employed to identify and determine the two effective components, say naringin and hesperidin. With the help of chemometric methods, say PCA, HCA and SA, the 38 herbal samples of FAI from various sources can be accurately differentiated. The method developed in this paper has demonstrated that it is able to discriminate between different herbal origins, detect the content of bioactive ingredients and systematically analyze traditional Chinese medicines, which offers a new clue for the study of traditional Chinese medicine. The results obtained will be helpful for quality control, rational herbal usage and pharmacodynamic research of herbal medicine.

Acknowledgements

The authors gratefully acknowledge the financial support from the International Co-operative Project of Science and Technology from the Ministry of Science and Technology of People's Republic of China (contract/grant number: 2007DFA40680), National Nature Foundation Committee of P.R. China (Grant No. 20875104 and 21075138), China Postdoctoral Science Foundation funded project (No. 20080440181), Special Foundation of China Postdoctoral Science (No. 200902481) and Central South University Science Development Foundation (No. 10SDF22).

References

  1. Chinese Pharmacopoeia Committee. Chinese Pharmacopoeia [M]. Publishing house of chemical industry, Beijing, 2005, pp. 118–119 Search PubMed.
  2. Y. T. Chen, R. L. Zheng, Z. J. Jia and Y. Ju, Free Radical Biol. Med., 1990, 9, 19–21 CrossRef CAS.
  3. S. V. Jovanovic, S. Steenken, M. Tosic, S. Steenken, B. Marjanovic and M. G. Simic, J. Am. Chem. Soc., 1994, 116, 4846–4851 CrossRef CAS.
  4. M. J. Martín, E. Marhuenda, C. Pérez-Guerrero and J. M. Franco, Pharmacology, 1994, 49, 144–150 CrossRef CAS.
  5. P. Zou, Y. Hong and H. L. Koh, J. Pharm. Biomed. Anal., 2005, 38, 514–520 CrossRef CAS.
  6. L. F. Hu, S. P. Li, H. Cao, J. J. Liu, J. L. Gao, F. Q. Yang and Y. T. Wang, J. Pharm. Biomed. Anal., 2006, 42, 200–206 CrossRef CAS.
  7. B. Y. Li, Y. Hu, Y. Z. Liang, P. S. Xie and Y. Ozaki, Analyst, 2006, 131, 538–546 RSC.
  8. K. Y. L. Yap, S. Y. Chan and C. S. Lim, Food Res. Int., 2007, 40, 643–652 CrossRef CAS.
  9. Y. Zhao, Z. W. Li, X. Zhou, Z. W. Cai, X. J. Gong and C. Y. Zhou, J. Pharm. Biomed. Anal., 2008, 48, 1230–1236 CrossRef CAS.
  10. W. J. Kong, Y. L. Zhao, X. H. Xiao, C. Jin and Z. L. Li, Phytomedicine, 2009, 16, 950–959 CrossRef CAS.
  11. Y. Y. Zhao, Y. M. Zhang, R. C. Lin and W. J. Sun, Fitoterapia, 2009, 80, 333–338 CrossRef CAS.
  12. L. Z. Yi, D. L. Yuan, Y. Z. Liang, P. S. Xie and Y. Zhao, Anal. Chim. Acta, 2009, 649, 43–51 CrossRef CAS.
  13. P. Mouly, E. M. Gaydou and A. Auffracy, J. Chromatogr., A, 1998, 800, 171–179 CrossRef CAS.
  14. L. Ding, X. B. Luo, F. Tang, J. B. Yuan, Q. Liu and S. Z. Yao, J. Chromatogr., B: Anal. Technol. Biomed. Life Sci., 2007, 857, 202–209 CrossRef CAS.
  15. X. M. Qin, Y. T. Dai, L. Z. Zhang, X. Q. Guo and H. X. Shao, Phytochem. Anal., 2009, 20, 307–313 CrossRef CAS.
  16. Y. Lu, C. Zhang, P. Bucheli and D. Wei, Plant Foods Hum. Nutr., 2006, 61, 57–65 CAS.
  17. C. Wand, Y. J. Pan, G. R. Fan, Y. F. Chai and Y. T. Wu, Biomed. Chromatogr., 2010, 24, 235–244 CAS.
  18. Q. Wang and Y. Dan, Heilongjiang Med. J., 2008, 21, 1–3 Search PubMed.
  19. T. Layloff, Pharm. Technol., 1991, 15, 146–148 Search PubMed.
  20. WHO, Guildlines for the assessment of herbal medicine. WHO: Geneva, 1996 Search PubMed.
  21. Drug Administration Bureau of China, Requirements for studying fingerprint of traditional Chinese medicine injection, Beijing, 2002 Search PubMed.
  22. W. J. Welsh, W. K. Lin, S. H. Tersigni, E. Collantes, R. Duta and M. S. Carey, Anal. Chem., 1996, 68, 3473–3482 CrossRef CAS.
  23. E. R. Collantes, R. Duta, W. J. Welsh and W. L. Zielinski, Anal. Chem., 1997, 69, 1392–1397 CrossRef CAS.
  24. T. I. Aksenova, I. V. Tetko, A. G. Ivakhnenko, A. E. P. Villa, W. J. Welsh and W. L. Zielinski, Anal. Chem., 1999, 71, 2423–2430 CrossRef CAS.
  25. L. B. A. Hansen, J. Pharm. Sci., 2001, 90, 943–948 CrossRef CAS.
  26. Y. Y. Cheng, M. J. Chen and W. D. Tong, J. Chem. Inf. Comput. Sci., 2003, 43, 1068–1076 CrossRef CAS.
  27. Y. Y. Cheng, M. J. Chen and W. J. Welsh, J. Chem. Inf. Comput. Sci., 2003, 43, 1959–1965 CrossRef CAS.
  28. L. J. Ni, P. Li, R. Zheng, L. G. Zhang and L. Z. Zhu, Chin. Trad. Pat. Med., 2002, 24, 79–82 Search PubMed.
  29. M. J. Chen, Y. Y. Cheng and R. C. Lin, Chin. Trad. Pat. Med., 2002, 24, 905–908 Search PubMed.
  30. X. Wang, W. Y. Wang, K. R. Zhang and K. S. Bi, J. Shenyang Pharm. Univ., 2003, 20, 360–363 Search PubMed.
  31. Y. P. Li, Z. Hu and L. C. He, J. Pharm. Biomed. Anal., 2007, 43, 1667–1672 CrossRef CAS.
  32. P. Zou, Y. Hong and H. L. Koh, J. Pharm. Biomed. Anal., 2005, 38, 514–520 CrossRef CAS.
  33. R. M. Yu, B. Ye, C. Y. Yan, L. Y. Song, Z. Zhang, W. Yang and Y. Zhao, J. Pharm. Biomed. Anal., 2007, 44, 818–823 CrossRef CAS.
  34. W. Li, Y. L. Deng, R. J. Dai, Y. H. Yu, M. K. Saeed, L. Li, W. W. Meng and X. S. Zhang, J. Pharm. Biomed. Anal., 2007, 45, 38–46 CrossRef CAS.
  35. X. H. Fan, Y. Wang and Y. Y. Cheng, J. Pharm. Biomed. Anal., 2006, 40, 591–597 CrossRef CAS.
  36. Y. X. Sheng, L. Li, Q. Wang, H. Z. Guo and D. A. Guo, J. Pharm. Biomed. Anal., 2005, 37, 805–810 CrossRef CAS.
  37. J. B. Xie, W. Q. Wang, Y. Q. Zhang, Y. Bai and Q. Yang, J. Pharm. Biomed. Anal., 2007, 45, 450–455 CrossRef CAS.
  38. X. D. Wen, L. W. Qi, P. Li, K. D. Bao, X. W. Yan, L. Yi and C. Y. Li, J. Chromatogr., B: Anal. Technol. Biomed. Life Sci., 2008, 865, 99–105 CrossRef CAS.
  39. Y. H. Wang, Z. Chen, D. X. Xiang and Y. R. Ou, Chin. Hosp. Pharm. J., 2006, 26, 910–913 Search PubMed.
  40. S. Kanno, A. Shouji, R. Hirata, K. Asou and M. Ishikawa, Life Sci., 2004, 75, 353–365 CrossRef CAS.
  41. U. J. Jung, M. Lee, Y. B. Park, M. A. Kang and M. Choi, Int. J. Biochem. Cell Biol., 2006, 38, 1134–1145 CrossRef CAS.
  42. A. Balakrishnan and V. P. Menon, Toxicology, 2007, 238, 90–98 CrossRef CAS.

This journal is © The Royal Society of Chemistry 2010